Patents by Inventor Jay A. Levy

Jay A. Levy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160030518
    Abstract: The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.
    Type: Application
    Filed: March 31, 2014
    Publication date: February 4, 2016
    Inventor: Jay A. Levy
  • Patent number: 5858374
    Abstract: A newly discovered family of AIDS-associated viruses, designated ARV, is described. The viruses were isolated from AIDS patients from San Francisco and (a) are type D retroviruses; (b) have Mg.sup.++ --dependent reverse transcriptase activity; (c) induce human multinucleated cells without immortalizing the cells; (d) are replicable in HUT-78 human T cells; and (e) induce viral protein(s) in HUT-78 that binds to Ig from AIDS patients. The infected HUT-78 cells and immunogenic polypeptides derived from the viruses are useful for diagnosing AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: University of California
    Inventor: Jay A. Levy
  • Patent number: 5736328
    Abstract: A newly discovered family of AIDS-associated viruses, designated ARV, is described. The viruses were isolated from AIDS patients from San Francisco and (a) are type D retroviruses; (b) have Mg.sup.++ -dependent reverse transcriptase activity; (c) induce human multinucleated cells without immortalizing the cells; (d) are replicable in HUT-78 human T cells; and (e) induce viral protein(s) in HUT-78 that binds to Ig from AIDS patients. The infected HUT-78 cells and immunogenic polypeptides derived from the viruses are useful for diagnosing AIDS.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: April 7, 1998
    Assignee: Regents of the University of California
    Inventor: Jay A. Levy
  • Patent number: 5707814
    Abstract: A protein secreted by peripheral blood mononuclear cells and specifically from CD8.sup.+ lymphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits vital replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay devices for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.
    Type: Grant
    Filed: March 5, 1996
    Date of Patent: January 13, 1998
    Assignee: The Regents of the University of California
    Inventors: Jay A. Levy, Carl E. Mackewicz
  • Patent number: 5580769
    Abstract: A protein secreted by peripheral blood mononuclear specifically from CD8.sup.+ lymphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay devices for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: December 3, 1996
    Assignee: The Regents of The University of California
    Inventors: Jay A. Levy, Carl E. Mackewicz
  • Patent number: 5565549
    Abstract: A protein secreted by peripheral blood mononuclear cells and specifically from CD8.sup.+ lyphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free, has a molecular weight of less than 30,000 and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay reagents for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: October 15, 1996
    Assignee: The Regents Of The University Of California
    Inventors: Jay A. Levy, Carl E. Mackewicz
  • Patent number: 5543131
    Abstract: Strains of HIV-2 capable of infecting humans and non-human primates such as baboons and causing an immune system disease are disclosed. The HIV-2 strain are used to infect non-human primates which infected primates present symptoms of a disease of the immune system and are used to test drugs, e.g., anti-virals and/or vaccines for their ability to treat and/or prevent lentiviral infections such as HIV infections. Useful strains are HIV-2.sub.UC2, HIV-2.sub.UC12 and HIV-2.sub.UC14 and preferred non-human primates are baboons.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: August 6, 1996
    Assignee: The Regents of the University of California
    Inventor: Jay A. Levy
  • Patent number: 5538856
    Abstract: The subject invention permits diagnosis of chronic fatigue syndrome (CFS) by analyzing peripheral blood mononuclear cell subset populations and activation markers. A positive diagnosis for CFS is associated with an increase in the percentage of CD8+ cells showing CD38 or HLA-DR cell markers or a decrease in CD11b markers in CD8+ cells. The analysis is preferably performed using fluorochrome-labelled monoclonal antibodies specific for a determinant of the above subset cells and activation markers.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: July 23, 1996
    Assignee: The Regents of the University of California
    Inventors: Jay A. Levy, Alan L. Landay
  • Patent number: 5426028
    Abstract: The subject invention permits diagnosis of chronic fatigue syndrome (CFS) by analyzing peripheral blood mononuclear cell subset populations and activation markers. A positive diagnosis for CFS is associated with an increase in the percentage of CD8+ cells showing CD38 or HLA-DR cell markers or a decrease in CD11b markers in CD8+ cells. The analysis is preferably performed using fluorochrome-labelled monoclonal antibodies specific for a determinant of the above subset cells and activation markers.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: June 20, 1995
    Assignees: Rush-Presbyterian-St. Lukes Medical Center, The Regents of The University of California
    Inventors: Jay A. Levy, Alan L. Landay
  • Patent number: 4716102
    Abstract: A newly discovered family of AIDS-associated viruses, designated ARV, is described. The viruses were isolated from AIDS patients from San Francisco and (a) are type D retroviruses; (b) have Mg.sup.++ -dependent reverse transcriptase activity; (c) induce human multinucleated cells without immortalizing the cells; (d) are replicable in HUT-78 human T cells; and (e) induce viral protein(s) in HUT-78 that binds to Ig from AIDS patients. The infected HUT-78 cells and immunogenic polypeptides derived from the viruses are useful for diagnosing AIDS.
    Type: Grant
    Filed: August 15, 1984
    Date of Patent: December 29, 1987
    Assignee: Regents of the University of California
    Inventor: Jay A. Levy